TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02613455
Drug: Kenalog (triamcinolone)
Normalized name: triamcinolone Injection [Kenalog]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
Study: NCT02613455
Drug: lidocaine 1% (lidocaine HCl 20mg)
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
Study: NCT01436539
Drug: Adefovir Dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir Dipivoxil 10 mg once daily for 48 weeks
Study: NCT00317798
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: escalating doses of rATG, intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
Study: NCT04340843
Drug: Belinostat
Normalized name: Belinostat
DrugBank: Belinostat (DB05015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00090103
Drug: dutasteride 0.5mg once daily for 4 years
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: combination or single agent
Study: NCT01421901
Drug: Ertapenem
Normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ertapenem i.v,m 1g, once a day, 3 days
Study: NCT01768455
Drug: Gemigliptin and Glimepiride
Normalized name: glimepiride and pioglitazone
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemigliptin 50mg (qd) on Day1\~Day6 and Gemigliptin 50mg (qd) and Glimepiride 4mg (qd) on Day7
Study: NCT01768455
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride 4mg (qd) on Day1
Study: NCT00976066
Drug: Part A Assessing GSK1521498
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will receive up to three \[11C\]carfentanil PET scans and up to two doses of GSK1521498 in total. The doses used will span the expected receptor occupancy range providing these were well tolerated in the first-time in human study.~Each subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively), followed by two treatment sessions (Treatment Sessions 1 and 2). Treatment session 1 and 2 are followed by PET scans and an fMRI scan (session 1 only). Sessions will be separated by at least 12 days. PET scans will be timed to coincide with peak brain occupancy. fMRI will begin approximately 30-60 minutes after completion of the PET scan.
Study: NCT00976066
Drug: Part B Assessing GSK1521498
Normalized name: SODIUM CHLORITE 0.0256 kg in 1 kg TOPICAL SPRAY [Chlorsan 105 Part B]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The purpose of Part B is to establish the timecourse of receptor occupancy of GSK1521498. Each participant in Part B will receive up to three \[11C\]carfentanil PET scans and one single oral dose of GSK1521498 expected to provide 50-75% receptor occupancy (selected with reference to data from Part A).~Each Part B subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of GSK1521498 followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).
Study: NCT00976066
Drug: Part C Assessing Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A range of doses of naltrexone will be tested in up to 12 participants in an adaptive design. Each Part C participant will receive up to three \[11C\]carfentanil PET scans and a single oral dose of naltrexone. No dose of naltrexone will exceed 50 mg, the dose usually used therapeutically in the treatment of opiate and alcohol dependence. Each Part C subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of naltrexone followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).
Study: NCT00656786
Drug: Menadione Topical Lotion
Normalized name: Menadione
DrugBank: Menadione (DB00170)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Menadione Lotion will be applied topically twice a day; beginning when the rash appears during EGFRi therapy.
Study: NCT00656786
Drug: Menadione Topical Lotion
Normalized name: Menadione
DrugBank: Menadione (DB00170)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Menadione Lotion will be applied topically twice a day, starting 1 day before EGFRi therapy.
Study: NCT00090103
Drug: tamsulosin 0.4mg once daily for 4 years
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: combination agent or single agent
Study: NCT03566329
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulphate 50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion. .
Study: NCT03566329
Drug: Lidocaine Hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine hydrochloride 1.5mg/kg loading followed by 2mg/kg/hr infusion
Study: NCT01737697
Drug: Zirconium silicate (subacute phase)
Normalized name: silicic acid
DrugBank: Silicic acid (DB14138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
Study: NCT04729868
Drug: Levobupivacaine(chirocaine) plus dexmedetomidine(precedex)
Normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: evaluate the efficacy of levo-bupivacaine alone and with dexmedetomidine in Ultrasound guided infraclavicular brachial plexus block for hand and forearm surgeries
Study: NCT00003997
Drug: irofulven
Normalized name: Irofulven
DrugBank: Irofulven (DB05786)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04340843
Drug: Guadecitabine
Normalized name: Guadecitabine
DrugBank: Guadecitabine (DB11918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC
Study: NCT04693000
Drug: Arsenic Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment
Normalized name: scabies lesion lysate (human)
DrugBank: Solasodine (DB18813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.Keratotic nodular size observation after 12 weeks
Study: NCT00598052
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg/day
Study: NCT00687518
Drug: Erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 50 U/kg of erythropoietin
Study: NCT04865705
Drug: tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilelizumab 200mg d1 Q3W Albumin Paclitaxel 260mg/m2 d1 Carboplatin/Cisplatin 75mg/m2/AUC5 d1 every 3 weeks
Study: NCT01871454
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pentoxifylline
Study: NCT02025426
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02025426
Drug: Ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00596375
Drug: Lidocaine Lubricant
Normalized name: Eyes Alive Lubricating
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2% Lidocaine lubricant instillation prior to urethral catheterization
Study: NCT04273178
Drug: Escalating prophylaxis
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For all patients without documented proven or probable invasive fungal disease (IFD), patients will receive fluconazole during the treatment in the laminar air flow units (LAF). After discharged from LAF units, patients will receive anti-mold prophylaxis in case of haplo-identical or HLA-matched unrelated donor transplantation to d+100 without active acute GVHD (aGVHD). In case of active aGVHD, the prophylaxis treatment will be extended until recovery of aGVHD and tapering of immunosuppression. In case of HLA-matched sibling donor, fluconazole will be continued to d+100 and anti-mold prophylaxis will be given in case of active aGVHD.
Study: NCT01916265
Drug: Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00034372
Drug: oregovomab
Normalized name: Oregovomab
DrugBank: Oregovomab (DB04964)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01262365
Drug: Epratuzumab
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
Study: NCT00804856
Drug: Volasertib
Normalized name: Volasertib
DrugBank: Volasertib (DB12062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
Study: NCT00804856
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Study: NCT01262365
Drug: Epratuzumab
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
Study: NCT04066088
Drug: Guanfacine extended release (GXR)
Normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The starting dose for all subjects will be 1 mg per day. If the medication is well-tolerated, the dose can be raised to 2 mg until day 28 and increased to 3mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed; the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8, the study will be unblinded and subjects will continue treatment for 8 more weeks.
Study: NCT04940143
Drug: Botulinum toxin type-A (Onabotulinum toxin type-A)
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin-A (Onabotulinum toxin type-A/Botox®) injection will be administered from three different points, two on the medial head of the gastrocnemius muscle and one point on the lateral head with total 3-6 units/kg dose, under the guidance of electrical stimulation for the detection of the target neuromuscular junction.
Study: NCT00648375
Drug: Propanolol
Normalized name: Propanolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take a 40-mg dose of propranolol immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
Study: NCT01017393
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01017393
Drug: ketamine free
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02507128
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide were taken 30 min before PCI.
Study: NCT02439125
Drug: Eltoprazine HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Eltoprazine (DB12883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg b.i.d. orally for 3 weeks
Study: NCT02439125
Drug: Eltoprazine HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Eltoprazine (DB12883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg b.i.d. orally for 3 weeks
Study: NCT02439125
Drug: Eltoprazine HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Eltoprazine (DB12883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg b.i.d. orally for 3 weeks
Study: NCT02207244
Drug: Guselkumab 100 mg
Normalized name: guselkumab 100 MG/ML
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.
Study: NCT00639249
Drug: SA4503 Low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration
Study: NCT00639249
Drug: SA4503 High
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT00781456
Drug: 91-day Levonorgestrel Oral Contraceptive
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
Study: NCT00568646
Drug: MKC-1
Normalized name: MKC-1
DrugBank: MKC-1 (DB05608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles
Study: NCT00705263
Drug: Ribavirin (SCH 18908)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
Study: NCT03729284
Drug: Cymbalta Capsules
Normalized name: Cymbalta
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.
Study: NCT03729284
Drug: Duloxetine Hydrochloride Capsules
Normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
Study: NCT02376309
Drug: ND
Normalized name: SAND
DrugBank: Schisandra chinensis fruit (DB14325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 nandrolone decanoate injection
Study: NCT00488982
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75mg/m2 every 21 days
Study: NCT00488982
Drug: Docetaxel and GM-CSF
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28
Study: NCT03801668
Drug: Albumin-bound Paclitaxel plus S-1
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Albumin-bound Paclitaxel 260mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
Study: NCT03801668
Drug: Oxaliplatin plus S-1
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
Study: NCT01148446
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1,4 mg/mq (max 2 mg)IV, day 1
Study: NCT01148446
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/mq IV, days 1-5
Study: NCT01148446
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/mq IV/PO, days 1-5
Study: NCT01148446
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/mq IV, day 1
Study: NCT01148446
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg/mq IV, day 1
Study: NCT01148446
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/mq IV, day 1
Study: NCT01148446
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 µg tot., SC; days 7-11
Study: NCT04230174
Drug: 11C-PBR28
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will evaluate, serially, functional and structural tissue changes in the cortex and WM of subjects with RRMS and progressive disease under Ocrelizumab using 11C-PBR28 MR-PET imaging at baseline and at approximately 12-month follow up.
Study: NCT03340610
Drug: Alflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Injection
Study: NCT00446966
Drug: Omega Three Polyunsaturated fatty acids
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.
Study: NCT00042874
Drug: alvocidib
Normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00042874
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01956591
Drug: Oxybutynin
Normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.
Study: NCT03316963
Drug: Neostigmine Methylsulfate
Normalized name: Neostigmine Methylsulfate
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate with co-administration of intravenous glycopyrrolate 0.2mg. At each of 5 injection sites on the soft palate , 0.5 mL (0.5mg) of neostigmine methylsulfate will be administered, yielding a total of 2.5mg (2.5mL) of neostigmine methylsulfate. The medication will be administered using five 1 mL syringes filled with 0.5 mL neostigmine each. Following administration of neostigmine, the patient will be observed for an additional 4 minutes to examine both vibration and sound emanating from the soft palate. The anticipated time under sedation will be 14 minutes.
Study: NCT03874052
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03874052
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00835575
Drug: Mirtazapine 15 mg (Orally Disintegrating) Tablets
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 15 mg, single-dose fasting
Study: NCT02322593
Drug: TAS-118 plus Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02322593
Drug: S-1 plus Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04476511
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet containing 30.000IU cholecalciferol
Study: NCT02207244
Drug: Placebo for guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).
Study: NCT02207244
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.
Study: NCT02458196
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 10mg/d to 12 months.
Study: NCT02458196
Drug: Prednisone and Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months.
Study: NCT02207244
Drug: Placebo for adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo for adalimumab \[two 0.8 milliliter (mL) injections\] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).